Tags

Type your tag names separated by a space and hit enter

The specific role of isoflavones in reducing prostate cancer risk.
Prostate. 2004 May 01; 59(2):141-7.P

Abstract

AIMS

To evaluate the effectiveness of supplementing a group of early stage prostate cancer patients, with 60 mg of soy isoflavones in producing a change in hormonal and proliferative risk parameters that are implicated in prostate cancer promotion.

METHODS

Seventy six eligible prostate cancer patients with a Gleason score of 6 or below, between ages 50 and 80 were admitted and supplemented with soy isoflavones or placebo for a 12 week period and changes in PSA and steroid hormones were analyzed at baseline and post intervention.

RESULTS

Fifty-nine patients completed the 12-week intervention. Serum free testosterone was reduced or showed no change in 61% of subjects in the isoflavone group compared to 33% in the placebo group. Serum total PSA decreased or was unchanged in 69% of the subjects in the isoflavone treated group compared to 55% in the placebo group. However, we did not see an increase in SHBG levels. Nineteen percent of subjects receiving soy isoflavones reduced total PSA by two points or more during the intervention period.

CONCLUSIONS

These data suggest that supplementing early stage prostate cancer patients with soy isoflavones, even in a study of short duration, altered surrogate markers of proliferation such as serum PSA and free testosterone in a larger number of subjects in the isoflavone supplemented group than the group receiving placebo. The study establishes the need to explore further the effects of prolonged and consistent soy consumption, which could potentially delay onset of histologic disease in this patient population.

Authors+Show Affiliations

Department of Nutrition, H. Lee Moffitt Cancer Center & Research Institute, University of South Florida, Tampa, Florida, USA. kumar@moffitt.usf.eduNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.

Language

eng

PubMed ID

15042614

Citation

Kumar, Nagi B., et al. "The Specific Role of Isoflavones in Reducing Prostate Cancer Risk." The Prostate, vol. 59, no. 2, 2004, pp. 141-7.
Kumar NB, Cantor A, Allen K, et al. The specific role of isoflavones in reducing prostate cancer risk. Prostate. 2004;59(2):141-7.
Kumar, N. B., Cantor, A., Allen, K., Riccardi, D., Besterman-Dahan, K., Seigne, J., Helal, M., Salup, R., & Pow-Sang, J. (2004). The specific role of isoflavones in reducing prostate cancer risk. The Prostate, 59(2), 141-7.
Kumar NB, et al. The Specific Role of Isoflavones in Reducing Prostate Cancer Risk. Prostate. 2004 May 1;59(2):141-7. PubMed PMID: 15042614.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The specific role of isoflavones in reducing prostate cancer risk. AU - Kumar,Nagi B, AU - Cantor,Alan, AU - Allen,Kathy, AU - Riccardi,Diane, AU - Besterman-Dahan,Karen, AU - Seigne,John, AU - Helal,Mohamad, AU - Salup,Raoul, AU - Pow-Sang,Julio, PY - 2004/3/26/pubmed PY - 2004/5/15/medline PY - 2004/3/26/entrez SP - 141 EP - 7 JF - The Prostate JO - Prostate VL - 59 IS - 2 N2 - AIMS: To evaluate the effectiveness of supplementing a group of early stage prostate cancer patients, with 60 mg of soy isoflavones in producing a change in hormonal and proliferative risk parameters that are implicated in prostate cancer promotion. METHODS: Seventy six eligible prostate cancer patients with a Gleason score of 6 or below, between ages 50 and 80 were admitted and supplemented with soy isoflavones or placebo for a 12 week period and changes in PSA and steroid hormones were analyzed at baseline and post intervention. RESULTS: Fifty-nine patients completed the 12-week intervention. Serum free testosterone was reduced or showed no change in 61% of subjects in the isoflavone group compared to 33% in the placebo group. Serum total PSA decreased or was unchanged in 69% of the subjects in the isoflavone treated group compared to 55% in the placebo group. However, we did not see an increase in SHBG levels. Nineteen percent of subjects receiving soy isoflavones reduced total PSA by two points or more during the intervention period. CONCLUSIONS: These data suggest that supplementing early stage prostate cancer patients with soy isoflavones, even in a study of short duration, altered surrogate markers of proliferation such as serum PSA and free testosterone in a larger number of subjects in the isoflavone supplemented group than the group receiving placebo. The study establishes the need to explore further the effects of prolonged and consistent soy consumption, which could potentially delay onset of histologic disease in this patient population. SN - 0270-4137 UR - https://www.unboundmedicine.com/medline/citation/15042614/The_specific_role_of_isoflavones_in_reducing_prostate_cancer_risk_ L2 - https://doi.org/10.1002/pros.10362 DB - PRIME DP - Unbound Medicine ER -